For more than a decade, US opioid policy has been guided by a compelling but incomplete story: aggressive pharmaceutical marketing and overprescribing by physicians flooded communities with addictive pills, igniting an epidemic of opioid use disorder (OUD) and death. This narrative drove sweeping supply-reduction measures, including dosage limits, forced tapers, patient abandonment, and intensified regulatory scrutiny of prescribers.

Click Here To Read The Article